Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT

Disc Medicine, Inc. (NASDAQ:IRON) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.  Morgan Stanley assumed coverage of the company’s stock with an “Overweight” rating and a price objective of $85, as reported by The Fly. The research firm highlighted bitopertin’s potential to reach the market faster than was earlier expected via an accelerated approval process. Furthermore, the firm expects additional upside potential from Disc Medicine, Inc. (NASDAQ:IRON)’s pipeline programs in anemia, particularly highlighting DISC-0974.

Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT

A scientist in a laboratory setting examining a sample of blood with a microscope.

The company has initiated APOLLO, which is a confirmatory clinical trial of bitopertin in adults and adolescents with EPP.  Disc Medicine, Inc. (NASDAQ:IRON) stated that 2025 is off to a robust start as it continues to make operational progress throughout the portfolio. The company opines that bitopertin has the potential to be a life-altering therapy. Furthermore, Disc Medicine, Inc. (NASDAQ:IRON) highlighted that, due to a strong financial foundation that offers a cash runway into 2028, it remains well-placed to progress the commercial preparation efforts for bitopertin and the development of the rest of its pipeline. The company had cash, cash equivalents, and marketable securities of $694.7 million as of March 31, 2025.

While we acknowledge the potential of IRON to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IRON and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.